|
HY-131326-25mg
|
MedChemexpress LLC
|
DOTA-tris(tBu)ester NHS ester [CAS 819869-77-7]
|
|
Cancer-programmed cell death
|
|
|
HY-131326-250mg
|
MedChemexpress LLC
|
DOTA-tris(tBu)ester NHS ester [CAS 819869-77-7]
|
|
Cancer-programmed cell death
|
|
|
HY-131326-50mg
|
MedChemexpress LLC
|
DOTA-tris(tBu)ester NHS ester [CAS 819869-77-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13218-10mg
|
MedChemexpress LLC
|
Acitazanolast [CAS 114607-46-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-13218-100mg
|
MedChemexpress LLC
|
Acitazanolast [CAS 114607-46-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-13218-25mg
|
MedChemexpress LLC
|
Acitazanolast [CAS 114607-46-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-13218-5mg
|
MedChemexpress LLC
|
Acitazanolast [CAS 114607-46-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-13218-50mg
|
MedChemexpress LLC
|
Acitazanolast [CAS 114607-46-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-134669-10mg
|
MedChemexpress LLC
|
CypK [CAS 1610703-09-7]
|
|
Cancer-programmed cell death
|
|
|
HY-134669-100mg
|
MedChemexpress LLC
|
CypK [CAS 1610703-09-7]
|
|
Cancer-programmed cell death
|
|
|
HY-134669-25mg
|
MedChemexpress LLC
|
CypK [CAS 1610703-09-7]
|
|
Cancer-programmed cell death
|
|
|
HY-134669-5mg
|
MedChemexpress LLC
|
CypK [CAS 1610703-09-7]
|
|
Cancer-programmed cell death
|
|
|
HY-134669-50mg
|
MedChemexpress LLC
|
CypK [CAS 1610703-09-7]
|
|
Cancer-programmed cell death
|
|
|
HY-134797-10mg
|
MedChemexpress LLC
|
p-SCN-Bn-deferoxamine [CAS 1222468-90-7]
|
|
|
|
|
HY-134797-5mg
|
MedChemexpress LLC
|
p-SCN-Bn-deferoxamine [CAS 1222468-90-7]
|
|
|
|
|
HY-138200-10mg
|
MedChemexpress LLC
|
Cy5 maleimide [CAS 1437796-65-0]
|
|
|
|
|
HY-138200-25mg
|
MedChemexpress LLC
|
Cy5 maleimide [CAS 1437796-65-0]
|
|
|
|
|
HY-138200-5mg
|
MedChemexpress LLC
|
Cy5 maleimide [CAS 1437796-65-0]
|
|
|
|
|
HY-138632-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-9 [CAS 2417370-42-2]
|
|
Cancer-programmed cell death
|
|
|
HY-138632-10mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-9 [CAS 2417370-42-2]
|
|
Cancer-programmed cell death
|
|
|
HY-138632-5mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-9 [CAS 2417370-42-2]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-10mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-5mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138635-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-12 [CAS 2417370-90-0]
|
|
Cancer-programmed cell death
|
|
